{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:49:49Z","timestamp":1789609789374,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,11]]},"abstract":"Abstract<\/jats:title>\n \n Aims<\/jats:title>\n In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight\/obesity but without diabetes who initiated semaglutide 2.4\u2009mg in real\u2010world settings.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n Individuals initiating semaglutide 2.4\u2009mg aged \u226545\u2009years with ASCVD and overweight\/obesity but without diabetes were identified in a US database (01\/01\/2016\u201312\/31\/2023) and matched 1:2 to those not on semaglutide based on a non\u2010parsimonious propensity\u2010score model. The primary outcomes included revised 3\u2010point MACE (rMACE\u20103: myocardial infarction, stroke, and all\u2010cause mortality) and revised 5\u2010point MACE (rMACE\u20105: rMACE\u20103, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE\u20103 and MACE\u20105, defined similarly to rMACE\u20103 and rMACE\u20105 but replacing all\u2010cause mortality with cardiovascular\u2010related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity\u2010related adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 9321 individuals on semaglutide 2.4\u2009mg were matched to 18,642 individuals not on semaglutide; patient characteristics were well\u2010balanced between cohorts. Over a mean follow\u2010up of 200\u2009days, semaglutide 2.4\u2009mg was associated with significantly lower risks of rMACE\u20105 (hazard ratio: 0.55;\n p<\/jats:italic>\n \u2009<\u20090.001), rMACE\u20103 (0.43;\n p<\/jats:italic>\n \u2009<\u20090.001), MACE\u20105 (0.65;\n p<\/jats:italic>\n \u2009<\u20090.001), and MACE\u20103 (0.58;\n p<\/jats:italic>\n \u2009<\u20090.01). Semaglutide 2.4\u2009mg was also associated with lower risks of all\u2010cause mortality, cardiovascular\u2010related mortality, hospitalisation for heart failure, and all exploratory outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this real\u2010world study of US individuals with ASCVD and overweight\/obesity but without diabetes, semaglutide 2.4\u2009mg was associated with significantly reduced risk of MACEs and other obesity\u2010related morbidities (NCT06874751).<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.70080","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:59:17Z","timestamp":1757480357000},"page":"6691-6704","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lower risk of cardiovascular events in patients initiated on semaglutide 2.4\u2009mg in the real\u2010world: Results from the\n SCORE<\/scp>\n study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)"],"prefix":"10.1111","volume":"27","author":[{"given":"Kim G.","family":"Smolderen","sequence":"first","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA"},{"name":"Section of Psychology, Department of Psychiatry Yale School of Medicine New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mena\u2010Hurtado","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc Plainsboro Township New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Michalak","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc Plainsboro Township New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Faurby","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc Plainsboro Township New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-3858","authenticated-orcid":false,"given":"B. Gabriel","family":"Smolarz","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc Plainsboro Township New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"University of Missouri\u2014Kansas City School of Medicine Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Song","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5317-1909","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Boland","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-1636","authenticated-orcid":false,"given":"Michael G.","family":"Nanna","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"4","key":"e_1_2_9_2_1","first-page":"504","article-title":"Obesity and obesity\u2010induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity","volume":"11","author":"Henning RJ","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae025"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.02.007"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028409"},{"key":"e_1_2_9_6_1","unstructured":"United States Food and Drug Administration.Highlights of Prescribing Information: WEGOVY(Semaglutide). Accessed January 15 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.28.23286515"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58719-y"},{"key":"e_1_2_9_10_1","unstructured":"Komodo Health Inc.Healthcare Map. Accessed January 15 2025.https:\/\/www.komodohealth.com\/technology\/healthcare-map"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.029190"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022376"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.048"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0754-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"issue":"3","key":"e_1_2_9_16_1","first-page":"141","article-title":"An empirical transition matrix for non\u2010homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen OO","year":"1978","journal-title":"Scand J Stat"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176344198"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0754-4"},{"issue":"1","key":"e_1_2_9_19_1","first-page":"85","article-title":"Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: a secondary analysis of the SELECT trial","volume":"18","author":"Plutzky J","year":"2025","journal-title":"Obes Facts"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2792"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.039177"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14593"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70080","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:23:05Z","timestamp":1771309385000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/dom.70080"],"URL":"https:\/\/doi.org\/10.1111\/dom.70080","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70080\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70080\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70080\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70080\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70080\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70080\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70080\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"2025-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}